Clinical Research Directory

Inclusion Criteria: * Age 18 to 75 years. * Clinically or pathologically confirmed hepatocellular carcinoma (HCC). * Unresectable HCC corresponding to CNLC stage IIa, IIb, or IIIa, without extrahepatic metastasis. * At least one measurable lesion according to RECIST version 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Child-Pugh class A or B liver function. * Adequate organ function, including an absolute neutrophil count ≥1.5 × 10⁹/L; platelet count ≥75 × 10⁹/L; hemoglobin ≥80 g/L; serum creatinine ≤1.5 × the upper limit of normal (ULN) or creatinine clearance ≥50 mL/min; total bilirubin ≤3 × ULN; and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN. * Suitable for treatment with lenvatinib and sintilimab according to institutional standards. * Able to understand and sign written informed consent. Exclusion Criteria: * Presence of extrahepatic metastasis. * Previous treatment with irreversible electroporation. * Prior systemic therapy that precludes treatment with lenvatinib or sintilimab. * Diffuse infiltrative HCC not suitable for IRE evaluation. * Uncontrolled ascites, hepatic encephalopathy, or active gastrointestinal bleeding. * Active severe infection requiring systemic treatment. * Active tuberculosis. * Uncontrolled hepatitis B virus replication despite antiviral therapy. * Clinically significant cardiovascular disease, including uncontrolled hypertension, recent myocardial infarction, unstable angina, or severe arrhythmia. * Concurrent malignancy requiring active treatment. * Pregnancy or breastfeeding. * Any condition that, in the investigator's judgment, would interfere with study participation or interpretation of the study results.